World News: 12:30 GMT Thursday 6th December 2018. [Pain Therapeutics, Inc. via Globe Newswire via SPi World News]
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, announced today the initiation of a Phase II study to evaluate PTI-125 as a potential first line treatment in patients with Alzheimer’s disease. This clinical study is supported by a research grant award from the National Institute on Aging (NIA), the primary Federal agency supporting new research in Alzheimer’s disease.
“There is a profound and timely need to develop new drugs for Alzheimer’s,” said Remi Barbier, President & CEO. “We are excited about the clinical potential of PTI-125, as this drug candidate represents a promising new approach for the treatment and prevention of Alzheimer’s.”
This Phase IIa study is designed to evaluate safety, tolerability, pharmacokinetics and biomarkers in 12 patients with mild-to-moderate Alzheimer’s treated with PTI-125 twice-daily for 1 month. In mid-2019, the Company expects to conduct a Phase IIb study in 36 patients with Alzheimer’s treated with PTI-125 for 3 months. Collectively, the Phase IIa and Phase IIb studies are intended to demonstrate target engagement, and possibly prepare PTI-125 for a pivotal efficacy program.
The science and technology for PTI-125 is published in prestigious peer-reviewed journals, including , and, and has been awarded multiple competitive research grants from the NIA.
The underlying science for PTI-125 also supports the development of a biomarker/diagnostic to detect Alzheimer’s disease with a simple blood test, possibly years before any symptoms appear.
Globe Newswire: 12:30 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.